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Abstract 
Background: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more 
readily available because of technological advances and reducing costs. The Genetic Testing in Epithelial 
Ovarian Cancer (GTEOC) Study explored the feasibility and acceptability of offering genetic testing to all 
women recently diagnosed with epithelial ovarian cancer (EOC). 
Methods: From 1st July 2013 to 30th June 2015 women newly diagnosed with EOC were recruited through six 
sites in East Anglia, UK. Eligibility was irrespective of patient age and family history of cancer. The 
psychosocial arm of the study utilised self-report, psychometrically validated questionnaires (Depression 
Anxiety and Stress Scale, DASS-21; Impact of Event Scale, IES) and cost analysis was performed. 
Results: 232 women were recruited and 18 mutations were detected (12 in BRCA1, 6 in BRCA2) giving a 
mutation yield of 8% which increases to 12% in unselected women <70 years (17/146) and 1% in unselected 
women >70 years (1/86). IES and DASS-21 scores in response to genetic testing were significantly lower than 
equivalent scores in response to cancer diagnosis (p<.001). Correlation tests indicated that whilst older age is 
a protective factor against any traumatic impacts of genetic testing, no significant correlation exists between 
age and distress outcomes. 
Conclusion: The mutation yield in unselected women diagnosed with EOC from a heterogeneous population 
with no founder mutations was 8% in all ages and 12% in women under 70. Unselected genetic testing in 
women with EOC was acceptable to patients and is potentially less resource-intensive than current standard 
practice.  
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Introduction 
Approximately 1.5% of women will be diagnosed with epithelial ovarian cancer (EOC) in their lifetime and, as 
a result of the relatively poor prognosis, it is the fifth commonest cause of cancer-related mortality in 
females. In the mid 1990s germline mutations in the BRCA1 and BRCA2 genes were identified in families with 
hereditary breast and ovarian cancer and testing for these genes is available through the NHS genetic service 
providing that the family history is sufficiently strong to instigate a referral (NICE guideline CG41). A woman 
with a mutation in the BRCA1 gene has a 40-60% lifetime risk of developing EOC[1]. For BRCA2 the lifetime 
risk is lower at 10–30%, but this is still around 10-fold elevated compared to the general population risk. At 
present there is no proven clinical screening for EOC [2] and unaffected women with completed families who 
carry BRCA1/BRCA2 mutations typically elect to have a prophylactic bilateral salpingo-oophorectomy that 
reduces the risk of EOC by 80–96% [3-5]. The prevalence of BRCA1/BRCA2 mutations in unselected women 
with ovarian cancers ranges from 8 to 22%[6-10], and this variation can in part be explained by the presence 
or absence of founder mutations in the study populations. In one study of 1,342 unselected patients with 
invasive ovarian cancer 161 BRCA1/BRCA2 carriers were identified in 1,038 women diagnosed with high-
grade serous (HGSOC) or endometrioid (EC) ovarian cancer (overall frequency 15.5%) confirming that 
inherited mutations in these genes account for a significant minority of all ovarian cancer cases [9]. The 
frequency of mutations was highest in the HGSOC group (135 carriers, 18%) but also significant in women 
with EC (26 carriers, 9%). Family history of breast or ovarian cancer was the best predictor of carrier status 
(33% had a first degree relative with breast or ovarian cancer) but 7.9% of all carriers had no significant 
family history. 
Genetic testing for mutations in BRCA1/BRCA2 was introduced into clinical practice in the late 1990s but 
because of the cost and technical complexity of testing it was initially limited to those cases where there was 
a greater than 20% probability of detecting a mutation (NICE guideline CG41), with the threshold being 
lowered to 10% since 2013 (NICE guideline CG164). Various models, such as BOADICEA [11] and the 
Manchester score [12], have been developed to estimate the probability of finding a BRCA1/BRCA2 
mutation. While these are extensively used in Clinical Genetics centres, they have in general not been 
incorporated into routine clinical practice outside of Clinical Genetics. Despite increasing awareness of 
BRCA1/BRCA2 in the medical community, referral rates vary considerably and many women are not referred 
for a genetic assessment; only 20% of the cohort studied by Zhang et al. had previously been referred for 
genetic testing [13] and as the referred group only contained 60% of all mutation carriers, it meant that 40% 
of mutation carriers were missed. If more mutation carriers can be identified this will increase the numbers 
of families where cascade genetic testing can be offered so that more female relatives at high risk of EOC 
and breast cancer can be identified, counselled and managed appropriately.  
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BRCA1/BRCA2 mutation carriers with EOC have a better short term survival compared with non-
BRCA1/BRCA2 women [14] and there is emerging evidence that BRCA2 mutation status in particular is likely 
to be an important prognostic and predictive marker in EOC with a significantly higher primary 
chemotherapy sensitivity rate [14 15] although the survival difference becomes less apparent over time [16]. 
It also appears that BRCA1/BRCA2 mutation status provides predictive information regarding likelihood of 
response to PARP inhibitors [17 18].  
In this study we explored the acceptability and feasibility of universal testing without pre-test genetic 
counselling BRCA1/BRCA2 in an unselected population of women who were within 12 months of being 
diagnosed with EOC. We used established metrics (the Depression Anxiety and Stress Scale, DASS-21 and the 
Impact of Event Scale, IES) to assess psychological distress, tailored questionnaires to gauge acceptability 
and undertook a detailed cost analysis to compare resource use with the standard genetic testing model. 
 
Methods 
Patient eligibility Patients were eligible if they were over 18 years old and had been diagnosed with high-
grade serous or endometrioid epithelial ovarian cancer within the last 12 months. Other ovarian cancer 
subtypes including low grade tumours were excluded as they are not part of the BRCA1/BRCA2 phenotype 
[9]. The study had full ethical approval (REC12/EE/0433). 
Patient recruitment: Women were recruited though six NHS hospitals of different sizes ranging from smaller 
district general hospitals to large regional centres (Figure 1). All women with ovarian cancer in the East 
Anglia region are managed in these six institutions, which allows for near-complete ascertainment of cases. 
Eligible women were approached by their treating clinician or specialist nurse. If the patient expressed 
interest in the study, information about the patient was passed to the study coordinator who provided the 
patient with detailed information about the study and obtained informed consent. Additionally the letter 
was sent to the patient to collect her demographic details and family history (Figure 2). No formal genetic 
counselling was given prior to testing.  
Genetic counselling and testing process: BRCA1/BRCA2 testing was performed in the clinically accredited 
laboratory of the East Anglian Genetics Service by Next Generation Sequencing and MLPA. If a gene 
mutation was identified the patient, her general practitioner and her treating clinician were informed by 
letter from the study team and a referral to the NHS clinical genetics service was requested for genetic 
counselling and cascade testing of other at-risk family members. Where variants of unknown significance 
(VUS) were identified these were also fed back to the participant, GP and her clinician by letter, and again a 
referral for genetic counselling was requested (Figure 2).   Only those women with mutations or VUS 
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received formal post-test genetic counselling via the standard clinical service. All family histories were 
assessed by a Geneticist when the mutation report was generated. If there was a clinically relevant family 
history that met standard referral criteria in women with no mutations this was noted in the results letter to 
the participant with advice to seek a genetics referral. 
 
Cost-analysis: In order to determine the resource implications of offering universal BRCA1/BRCA2 testing in 
an unselected population of women within 12 months of being diagnosed with EOC we undertook a cost-
analysis. We mapped both the existing (current standard) referral and testing pathway (Figure S1) and the 
new proposed referral and testing pathway (Figure S2). Once these pathways were mapped, we defined the 
service activities and determined the resources required to undertake these activities using a ‘bottom-up’ 
micro-costing approach in order to calculate the overall cost for both pathways. Costs are reported in 2015 
UK £ and from the perspective of the clinical genetics service from referral for genetic testing to diagnostic 
BRCA1/BRCA2 test outcome of the index case. Market prices taken from the NHS test directory hosted on 
the UKGTN website (http://ukgtn.nhs.uk) were used for the actual genetic testing of BRCA1/BRCA2. The cost 
of staff (administrators and clinical staff) were obtained from both the NHS agenda for change (2015) and 
the Personal Social Services Research Unit (PSSRU) reference costs for 2014/2015. We used the mid-point of 
each grade and included National Insurance, superannuation and overhead costs if they were not already 
included. All cost data collected are reported in Table S1. Here we report the average testing pathway cost 
per BRCA1/BRCA2 mutation identified, the average testing pathway cost per genetic test offered, and the 
overall budget required for the 232 EOC patients eligible for inclusion within the GTEOC study. 
The main (base case) analysis assumes that in addition to those meeting the Manchester score for genetic 
testing (n=63 of the 232 EOC patients), half (50%) of those affected by epithelial ovarian cancer were also 
referred through to the cancer genetics service to have their family history checked before determining 
whether they would have genetic testing. The base case analysis does not have an age cut-off and no 
discount rate has been applied given that all patients would expect to receive the result of their genetic test 
within a year. 
Cost-analysis sensitivity analysis: Sensitivity analyses allow insight into which assumptions or limitations to 
the data included are important to the overall result or conclusion drawn from the analysis. A pragmatic 
approach to conducting one-way sensitivity analyses was undertaken and included varying the cost of the 
genetic test (assay price in both pathways), percentage of patients referred to the cancer genetics service in 
the existing current testing pathway (from 0% of patients not meeting the Manchester score to 100% i.e. all 
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patients offered initial appointment in cancer genetics service), and limiting the genetic testing within the 
GTEOC testing pathway to women under 70.  
Psychological impact and acceptability analysis: All participants who underwent genetic testing were asked 
to complete a short, self-report questionnaire which was sent to them by post to limit intrusion.  This 
included the Depression, Anxiety and Stress Scale (DASS-21)[19] and the Impact of Event Scale (IES)[20].  
Each scale was presented twice: once anchored to the psychological impact of diagnosis of ovarian cancer, 
and a second time anchored to the psychological impact of the genetic test.  A further twelve study-specific 
questions assessed the acceptability of this method of genetic testing. 
Results 
A total of 232 of 281 eligible women (83%) were consented to participate and tested over the study period. 
Almost all (98%) participants reported their ethnicity as white British, in keeping with the demographic 
profile of the region (Table 1). The mean age of the participants was 63 years (range 30-90 years) and two-
thirds of the participants were 60 years or older which is consistent with the observed age profile in women 
diagnosed with EOC. One hundred and ninety one participants (82%) had high-grade serous ovarian cancer, 
20 (9%) had endometrioid OC, 15 (6%) had unspecified or poorly differentiated adenocarcinomas and six 
(2.5%) were mixed types. The median time from consent to results delivered was 46 working days (range 15-
117 days). The mean time from sample receipt to results delivered was 39 working days (range 11- 111 
days). Overall, 175 women (75%) had stage III or IV disease. Educational levels were available on 166 
participants (72%) and in this group of women 100  (60%) had completed secondary education only, 37 
(22%) had completed a diploma and 25 (15%) were educated to degree level (Table 1).  
Eighteen BRCA1/BRCA2 predicted loss-of-function mutations were detected (12 in BRCA1, six in BRCA2) 
giving an overall prevalence of 8% (Table 2). None of the mutations were common founder mutations seen 
in other populations (Table S2)[21]. The mean age of mutation carriers was 50 years (range 40-75 years) with 
a mutation prevalence of 12% in women under 70 years of age (17/146) and 1% in unselected women 70 or 
older (1/86).  
In women under 70 years of age with a positive family history (affected first- or second-degree relative) the 
mutation prevalence 17% (13/77), but one quarter of the carriers in this age group had no family history.  Six 
mutation carriers had a previous personal history of breast cancer (Table 2). All twelve BRCA1 and five of the 
BRCA2 mutation positive cases had high-grade serous ovarian cancer (Table 2). The other BRCA2 mutation 
positive case had a high-grade adenocarcinoma with features suggestive of an endometrioid 
adenocarcinoma. Seventeen VUS were detected in 15 patients, 14 in BRCA1 and 3 in BRCA2. 
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All 12 BRCA1 and five of the BRCA2 mutation positive cases had serous papillary type ovarian cancer (Table 
2). One of the BRCA2 mutation positive cases had high grade adenocarcinoma with features in favour of a 
grade 3 endometrioid adenocarcinoma.  
Psychological impact: 173 questionnaires were returned (75%). IES (cognitive intrusion i.e. unwanted 
intrusive thoughts about the phenomenon, avoidance behaviour, hyperarousal i.e. a state of 
increased psychological and physiological tension) and DASS-21 (depression, anxiety and stress) scores in 
response to genetic testing were significantly lower than equivalent scores in response to cancer diagnosis 
(Wilcoxon Signed Rank tests Z-score range = -6.174 to -8.852; all p<.001). Essentially, having the genetic test 
did not increase distress or psychological traumatic response beyond that already being experienced as a 
result of the cancer diagnosis itself. Younger participants found the test to lead to more intrusive thoughts 
(IES intrusion r=-.172, p=.026), and significantly more stress (DASS stress r=.162, p=.014).  There were no 
significant differences based on age for IES avoidance IES hyperarousal, DASS anxiety or DASS depression. 
There were no significant differences on any IES or DASS subscale by education level, cancer stage, 
Manchester Score or previous cancer history. A significant difference was found in cognitive avoidance 
scores based on categorisation of BRCA mutation status (p=.036), with highest mean scores reported by 
those with a BRCA1 or BRCA2 mutation.  The study population was not sufficiently heterogeneous to explore 
any differences based on either ethnicity or country of birth.  
Acceptability of the test: High levels of acceptability were reported (Table 3) and participants felt they had 
enough information and time to proceed with genetic testing. Most women talked to their family about the 
test and felt that the test gave them a better understanding of their family’s risk. The widest variation in 
scores related to the perceived level of ease with which participants made the decision to proceed with 
genetic testing. 
Cost analysis: For the base case analysis, the overall budget, the average patient pathway cost per 
BRCA1/BRCA2 mutation positive, and the average patient pathway cost per test offered for the current 
pathway were £142,702, £11,892, and £2,265, respectively. For the GTEOC patient pathway, these costs 
were £253,617, £14,919 and £1,093, respectively (Table S2). The larger budget for the GTEOC patient 
pathway represents the increased cost due to a significantly greater number of genetic tests undertaken. 
When the cost of the genetic testing is removed from the cost of the patient pathway, the budget for GTEOC 
patient pathway is lower (£56,166 versus £88,633 for the current patient pathway). The non-genetic test 
related costs within the GTEOC patient pathway account for approximately 22% of the budget compared to 
62% for the current patient pathway within the base-case analysis. The average patient pathway cost per 
patient without the genetic testing for the GTEOC and the current testing patient pathway are £243 and 
£383, respectively. 
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Sensitivity analysis: The results of the sensitivity analysis show that changing the cost of the genetic test has 
a large impact on the budget, the average patient pathway cost per BRCA1/BRCA2 positive and also the 
average testing pathway cost per test offered for both pathways (Table S2). If the cost of the genetic test 
were to come down to £190, the budget required for the GTEOC pathway would be the same as the current 
pathway ceteris paribus in the base case analysis. Changing the number of women referred to the cancer 
genetics service impacts on the budget required for the existing pathway. Implementing the age cut-off for 
eligibility of genetic testing in the GTEOC pathway has a large impact on the budget required to test the 232 
eligible women. Even with a genetic test price of £650 (the current price of a clinical exome), implementing 
the age cut-off within the GTEOC patient pathway would lead to a lower budget for the GTEOC pathway 
(£121,229 versus £130,102 for the current patient pathway). 
Conclusions 
The primary objective of the study was to determine the feasibility, acceptability and cost-effectiveness of Is 
screening all newly diagnosed women with EOC for BRCA1/BRCA2 mutations by determining the mutation 
prevalence, calculating cost per gene mutation detected and assessing psychological impact based on 
questionnaire responses and qualitative interviews. 
The mutation prevalence in an unselected cohort of women diagnosed with EOC from a heterogeneous 
population with no founder mutations was 8% in all ages and 12% in women under 70 years. This is similar 
to that reported in a combined study of two large case-control OC series (one of which included cases from 
the East Anglia region)[8], but lower than that the frequency of 15% reported a recent study by Norquist et 
al. [10]. These differences are likely to be partly explained by the presence or absence of founder mutations 
in the test populations as 13% of all the BRCA1/BRCA2 mutations identified in the Norquist study were those 
commonly found in individuals of Ashkenazi Jewish descent. 
The cost-analysis undertaken here provides some insight into the potential delivery of BRCA1/2 genetic 
testing in a cohort of women diagnosed with EOC. The burden of cost in the provision of genetic testing lies 
in the provision of diagnostic testing for the current patient pathway (62% of costs are non-genetic test 
related) whereas with the GTEOC pathway the burden lies with the cost of the genetic testing itself (only 
22% of costs were non-genetic test related). Furthermore, given the high price of genetic testing used within 
the base-case, when a more realistic current day price is included as a sensitivity analysis and is coupled with 
the use of an age cut-off, the GTEOC patient testing pathway is likely cost-saving compared to the current 
testing pathway for this patient cohort. However, a clear limitation of this analysis is the exclusion of the 
costs involved in the clinical management of these patients as these costs are likely to be significant when 
cascade testing is also included into the ‘patient’ pathway. 
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Based on our findings we would recommend offering testing to all women under 70 years of age as the 
mutation prevalence would be above the current threshold of 10% used for eligibility for testing breast 
cancer families in the UK (NICE CG164). This age cut-off would also improve the mutation: VUS ratio from 1:1 
to 2:1.  By not testing those over 70 years it is possible to reduce the number of tests by around 37% and 
miss only 6% of all mutations. Indeed, in this study both women over the age of 70 years with mutations had 
a family history of breast or ovarian cancer. No mutation carriers would have been missed by using the 
criteria of 1) age under 70 years, or 2) 70 years and over with a previous history of breast cancer or history of 
breast or ovarian cancer in a first degree relative.   
A key question of the GTEOC study was whether outcome of the genetic test affects IES or DASS-21 scores. 
Our study investigated the hypothesis that psychological response to the genetic test may lead to increased 
distress beyond that of the cancer diagnosis itself.  Methodologically, this was difficult to test and we used 
the approach of including each psychological measure twice (with different anchoring) to let participants 
distinguish their psychological responses to the genetic test from their psychological response to the cancer 
diagnosis itself.  That participants responded differently to identical questions anchored to each event 
suggests that this is a useful methodology; mean ratings on all subscales of both the IES and the DASS were 
significantly higher for diagnosis than for the genetic test, consistent with previous findings in breast cancer 
patients [22]. We also investigated whether the psychological response to the genetic test would be affected 
by participant demographics.  Correlation analyses indicated no significant effects of age on depression, 
anxiety cognitive avoidance or hyperarousal; significant negative correlations indicate an inverse relationship 
between younger age and higher levels of perceived stress and cognitive intrusion.  This result fits the 
pattern of broader literature on the psychological impact of cancer diagnosis and treatment, whereby 
adjustment is typically worse in those diagnosed at a younger age [23]. Those later found to have a genetic 
mutation scored significantly higher on cognitive avoidance, but no differences in other subscales assessed 
were identified.  Self-reported acceptability data were favourable and support the value and acceptability of 
the testing procedure in this sample. 
Genetic counselling protocols have evolved from a paradigm initially developed in the context of predictive 
testing for Huntington’s disease (HD). Due to concerns about the negative and potentially grave impact of 
receiving a molecular diagnosis of HD, a protocol involving two face-to-face pre-test appointments and 
follow up was developed [24]. It has long been thought that this level of support may not be required in the 
diagnostic setting[25] and with the advent of targeted therapies the need for systematic genetic testing has 
become more pressing, but current pathways are not designed for high volume testing. One solution would 
be to devolve genetic testing completely to the oncologists but this approach fails to take advantage of the 
comprehensive clinical genetic networks that exist in most countries. There are also other concerns 
 10 
regarding this approach; the interpretation of VUS may not be adequate[26], and cascade testing within 
families may not occur (Figure 3).   
A unique strength of this study is the near complete ascertainment of women with ovarian cancer recruited 
through both secondary and tertiary referral centres in a clearly defined geographical region which is highly 
representative of clinical services throughout the UK and internationally. These findings are therefore likely 
to be widely applicable, and similar novel approaches have been trialled in other countries such as Norway 
[7]  and The Netherlands [27] Even though overall numbers tested are relatively small, the participation rate 
was high and the mutation yield is consistent with those reported in other studies in heterogeneous 
populations lacking founder mutations. One weakness is the lack of ethnic diversity in the study participants 
which reflects the relative homogeneity of the East Anglian population (91% white Caucasian for all ages; 
Office for National Statistics, 2011 Census data from KS201EW). Further studies would be required to assess 
acceptability in more ethnically diverse regions.  
These results show universal genetic testing in women with a diagnosis of EOC to be an acceptable and 
sensitive procedure:  these women have much emotional work to do as they confront their diagnosis, 
mortality and the impact on family members. Our data show that this type of genetic testing does not 
increase distress or traumatic response significantly beyond that already experienced following cancer 
diagnosis.  Older age was a protective factor against traumatic response, but not distress. Comprehensive 
case-based genetic testing appears to be acceptable to patients and is less resource-intensive than standard 
current practice where all women are referred for genetic counselling prior to testing. 
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Tables 
 
Demographic n 
Mean Age, years (range) 64.3 (30-90) 
Country of Birth 
UK 224 (97%) 
Other 8 (3%) 
Ethnicity 
Caucasian 226 (98%) 
Other 6 (2%) 
Pathology 
Serous 192 
Endometrioid 20 
Adenocarcinoma 15 
Mixed 5 
Stage 
I 34 
II 6 
III 137 
IV 42 
Not classified 13 
Educational Status 
(total n=166) 
Degree 25 (15%) 
Diploma 37 (22%) 
Secondary 100 (60%) 
 
 
Table 1 Study population demographics 
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Table 2 – Age at diagnosis and pathology characteristics of BRCA1/BRCA2 mutation carriers  
  
 BRCA1/2+ ( n= 18) BRCA1/2 VUS ( n=15) Non-BRCA1/2 (n= 199) 
Mean Age ( Range) 49.5 (40-75) 64.8 (41-84) 66.1 (30-90) 
BRCA1 12 (67%) 3 (20%) N/A 
BRCA2 6 (33%) 12 (80%) N/A 
Pathology:    
High grade serous 15 11 166 
Endometrioid 1 4 15 
Adenocarcinoma 2 0 13 
Mixed types 0 0 5 
Stage:    
I 4 5 25 
II 0 0 6 
III 12 9 116 
IV 2 1 39 
Not classified 0 0 13 
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Question n 
Mean 
Score 
SD 
Q1: I was pleased to have the option of genetic testing 
High mean score = pleased to have option of genetic test 
173 5.72 .846 
Q2: I had access to enough information to make a decision about testing 
High mean score = had enough information to make decision 
174 5.61 .953 
Q3: It was difficult to decide whether to have the genetic test 
 Low mean score = easy to make decision 
172 2.05 1.80 
Q4: I had enough time to think about whether to have the genetic test  
High mean score = had enough time to make decision 
174 5.43 1.29 
Q5: I found genetic testing to be useful to me  
High mean score = genetic test was useful 
172 5.49 1.07 
Q6:  I was reassured by my genetic test results 
High mean score = reassured by test results 
173 5.30 1.30 
Q7: The genetic test results allowed me to better understand my cancer risks 
High mean score = test allowed better understanding of cancer risks 
173 5.00 1.48 
Q8: The genetic test results allowed me to better understand my family’s cancer 
risks 
High mean score = test allowed better understanding of family’s risk 
173 5.31 1.26 
Q9: This was a good time for me to have the genetic test 
High mean score = good time to have test 
171 5.43 1.19 
Q10: I would have preferred to wait before I had genetic testing 
Low mean score = wouldn’t have wanted to wait before test 
171 1.49 1.21 
Q11:  I found genetic testing to be stressful 
Low mean score = didn’t find it stressful 
170 1.75 1.53 
Q12: I was satisfied with the support I received from family and friends 
High mean score = satisfied with family / friend support 
168 5.52 1.13 
Q13: I talked to my family about my genetic test 
High mean score = most talked to their family about the test 
169 5.73 1.15 
 
Table 3 – Quantitative analysis of acceptability using 13 tailored questions 
Possible Score range was 1.0 (min) to 6.0 (max) 
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  Figure Legends 
 
 
 
 
Figure 1. The location of hospitals in the Anglia region and number of patients recruited at each site. 
Figure 2.  The GTEOC Testing Protocol 
Figure 3. Models of Service delivery for Genetic Testing 
 
